• Female or male patients ≥ 18 years of age.

• Histologically confirmed diagnosis of invasive breast cancer, previously untreated.

• Participants must have biopsy proven ER negative (ER-), PR negative (PR-), HER2 negative (HER2-), invasive breast cancer. ER, PR, and HER2 positivity would be determined per ASCO/CAP guidelines by institutional (local) assessment. Patients with multi-focal and multicentric disease are eligible provided all histologically examined lesions are ER-/PR-/HER2- (local assessment). The need to biopsy additional lesions is at the discretion of the treating physician. Patients with bilateral invasive breast cancer are eligible provided all histologically examined lesions are ER-/PR-/HER2- (local assessment).

• Primary tumor (at least one lesion) 1 cm or greater measured by radiological imaging. Regional lymph node AJCC (v7) TNM stages N0-N2. If node positive, any primary tumor size is permissible. Absence of distant metastatic disease (AJCC TNM stage M0). Staging scans are not required and are per discretion of the treating physician.

• Pre- and postmenopausal women are eligible.

• ECOG performance status = 0, 1 (Karnofsky ≥60%, see Appendix A)

• Ability to understand and the willingness to sign a written informed consent form (ICF). Patient has signed the ICF prior to any screening procedures being performed and is able to comply with protocol requirements, including research biopsy.

• Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:

• Absolute neutrophil count (ANC) ≥ 1,500 per mm3

• Platelets ≥ 100,000 per mm3

• Hemoglobin ≥9.0 g/dL

• INR ≤1.5

• Serum creatinine \<1.5 mg/dL or creatinine clearance ≥50 mL/min

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN.

• Total bilirubin ≤1.5 x ULN or in patients with well-documented Gilbert's Syndrome direct bilirubin ≤1.5 x ULN.